Work

Comparing plasma p-tau217 and plasma p-tau217/Aβ42 with CSF biomarkers for assessing Alzheimer’s disease pathology

Year: 2026
Type: article
Study design: Observational Study
Abstract: Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ 42 ) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ 42 /Aβ 40 and p-tau181/Aβ 42 ) for identifying AD pathology (Aβ-PET visual read) across a memory clinic ( n = 129), a primary care ( n = 220) and a research cohort ( n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ 42 (83–92%) had comparable accuracies to CSF (88–90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90–97%) remained comparable to CSF (91%) in the clinical cohorts (all P adj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ 42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.
Source: Nature Aging
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $12,690
Awards: G1012222616, G1120803110, G1298807586, G1304444302, G1469549138, G1554142629, G1593117279, G1650819308, G1880935189, G2043619954, G2100670906, G2152643862, G2189010064, G2340207221, G2423387114, G2465228561, G2471646051, G2522063444, G2835601961, G29951154, G3131374986, G3277900835, G3553156159, G3678370191, G3710456697, G3752451908, G3870774570, Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease, G3908963977, G3966393351, G4038479886, G4196769506, G43180419, G4501223628, G4800177743, G4977467247, G5184609404, G5207404921, G5209990037, G528601746, G5365730499, G5524304478, G5585422332, G5654639750, G5740349702, G6011188351, G613619302, G6173816828, G6210868510, G6365185080, G6371410416, G6412110892, G6447063303, G6719828067, Prospective validation of high-performing blood biomarkers and digital cognitive tests in both specialist memory clinic and general primary care settings, G6792506723, G681300203, G6899163935, G7021656695, G7153071485, G72415811, G7298697282, Development of biomarkers in Alzheimer’s disease: improvement of early and accurate diagnosis and increased understanding of disease mechanisms that facilitates drug development, A precision medicine approach for the diagnosis and prognosis of preclinical Alzheimer´s disease with implications for clinical trials, G764699806, G7799614282, G781725486, G8019856391, G822442210, G8228018387, G8281378126, G839208290, G8598463824, G8852128998, G8895907669, G8897063270, G8917015137, G8957659042, G9000122335, G9000360447
OpenAlex ID: W7235972385
FWCI:
Cites: 28
Cited by:
Related to: 10